Tiziana Life Sciences (TLSA) said Tuesday the ALS Association has approved its grant application for funding a 20-participant clinical study of two doses of its intranasal foralumab candidate to treat amyotrophic lateral sclerosis.
The company said it will receive the funding as part of the Hoffman ALS Clinical Trial Awards Program.
Terms of the funding weren't disclosed.
Tiziana said it is also evaluating intranasal foralumab in a phase 2a multicenter, dose-ranging study in patients with non-active secondary progressive multiple sclerosis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments